Clinical Trial Update: Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I) [Phase 3]

View source ↗

Summary

This clinical trial update covers a Phase 3 study evaluating BBP-418 (ribitol) for limb-girdle muscular dystrophy type 2I (LGMD2I), with the study currently act…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Limb-girdle Muscular Dystrophy Type 2i

Drugs mentioned

• BBP-418 (Ribitol) (ribitol)

Snippet

Sponsor: ML Bio Solutions, Inc. | Conditions: Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I) | Phase 3 | Status: ACTIVE_NOT_RECRUITING